UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~July~~February 10 7, ~~2006~~2007

ASPREVA PHARMACEUTICALS CORPORATION

(Exact Name of Registrant as Specified in Charter)

British Columbia, Canada

(State or Other Jurisdiction of Incorporation)

000-51169	98-0435540
(Commission File Number)	(IRS Employer Identification No.)

1203-4464 Markham Street

Victoria, British Columbia, Canada V8Z 7X8

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (250) 744-2488

Not Applicable (Former name or former address, if changed since last report)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On ~~July~~February 107, ~~2006~~2007, Aspreva Pharmaceuticals Corporation issued a press release announcing its ~~preliminary~~financial ~~revenues~~results for the ~~second~~ quarter ended December 31, 2006 and the fiscal year ended December 31, 2006. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Aspreva Pharmaceuticals Corporation whether made before or after the date hereof, regardless of any general incorporation language in such filing.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits:

Exhibit No.		Description
99.1		Press Release entitled “Aspreva ~~Announces~~Pharmaceuticals ~~Preliminary~~Reports ~~Revenues~~2006 ~~for~~Fourth ~~Second~~ Quarter ~~2006~~and Year End Results and Provides 2007 Revenue Guidance,” dated ~~July~~February 107, ~~2006~~2007.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ASPREVA PHARMACEUTICALS CORPORATION
Dated: July 17, 2006
Dated: February 7, 2007
	By:	/s/ Bruce G. Cousins
		Bruce G. Cousins
		Chief Financial Officer

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release entitled “Aspreva ~~Announces~~Pharmaceuticals ~~Preliminary~~Reports ~~Revenues~~2006 ~~for~~Fourth ~~Second~~ Quarter ~~2006~~and Year End Results and Provides 2007 Revenue Guidance,” dated ~~July~~February 107, ~~2006~~2007.

Filing Compare · Aspreva Pharmaceuticals CORP